Inflexion, a mid-market private equity firm, completed the investment in Proteros biostructures, a contract research organization focused on early-stage drug discovery. Financial terms were not disclosed. “I am excited to have Inflexion on board as a partner. Their track record in backing innovative businesses combined with their operational experience within all areas of rapidly growing companies gives me great conviction they are well placed to support Proteros in its further growth trajectory," Torsten Neuefeind, Proteros Founder and CEO.